

Boston Scientific

Boston Scientific Announces 30-day Safety Data for High-Risk Patient Carotid Stenting Trial

(April 22, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced 30-day safety data from its clinical trial to evaluate the benefits of stenting in conjunction with embolic protection for the treatment of carotid artery disease. Christopher White, M.D., Co-Principal Investigator of the BEACH trial, Director of the Ochsner Heart and Vascular Institute in New Orleans and Chairman of Ochsner

<https://stage.mediaroom.com/bostonscientific/news-releases?item=58604>